Biotech | October 27, 2025
Novartis to acquire Avidity Biosciences for $12 billion
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
Subscribe To Our Newsletter & Stay Updated
